Unmet needs

Unmet needs

Although current therapies are effective at preventing vision loss and frequently result in visual gain for patients with both Proliferative Diabetic Retinopathy and Diabetic Macular Edema, unmet treatment needs still exist. A substantial proportion (40%–50%) of eyes with Diabetic Macular Edema do not respond fully to anti-VEGF (VEGF=Vascular Endothelial Growth Factor; anti-VEGF therapy is the current gold standard treatment) treatment or become refractory to it, necessitating the development of novel therapies for this condition. For both Proliferative Diabetic Retinopathy and Diabetic Macular Edema, non-invasive, non-destructive, and longer-duration treatment options are also needed. Further research into the molecular pathways involved in the progression and the development of Diabetic Retinopathy and Diabetic Macular Edema may provide novel therapeutics in the future.